Kiniksa Pharmaceuticals, Ltd. KNSA
We take great care to ensure that the data presented and summarized in this overview for Kiniksa Pharmaceuticals, Ltd. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding KNSA
View all-
Pictet Asset Management Sa Geneva 73, V81.52MShares$34.8 Million0.03% of portfolio
-
Spearhead Capital Advisors, LLC Wellington, FL203KShares$4.65 Million2.82% of portfolio
-
Harbor Capital Advisors, Inc.98.1KShares$2.25 Million0.08% of portfolio
-
Putnam Investments LLC Boston, MA39.5KShares$906,9930.0% of portfolio
-
Birchview Capital, LP Burlington, VT30KShares$689,1000.51% of portfolio
-
Credit Suisse Ag Zurich, V828.9KShares$664,3840.0% of portfolio
-
Virginia Retirement Systems Et Al Richmond, VA25.2KShares$578,8440.0% of portfolio
-
Exane Derivatives9.5KShares$218,1230.06% of portfolio
Latest Institutional Activity in KNSA
Top Purchases
Top Sells
About KNSA
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
Insider Transactions at KNSA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 20
2025
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
15,944
-40.54%
|
$366,712
$23.11 P/Share
|
|
Mar 20
2025
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
15,944
+28.85%
|
$191,328
$12.97 P/Share
|
|
Mar 19
2025
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
8,879
-27.52%
|
$204,217
$23.1 P/Share
|
|
Mar 19
2025
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
8,879
+21.58%
|
$106,548
$12.97 P/Share
|
|
Mar 17
2025
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
11,464
-32.9%
|
$263,672
$23.1 P/Share
|
|
Mar 17
2025
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
11,464
+24.75%
|
$137,568
$12.97 P/Share
|
|
Mar 16
2025
|
Eben Tessari CHIEF OPERATING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
577
-0.73%
|
$12,694
$22.61 P/Share
|
|
Mar 16
2025
|
Eben Tessari CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,964
+2.44%
|
-
|
|
Mar 16
2025
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
328
-1.18%
|
$7,216
$22.61 P/Share
|
|
Mar 16
2025
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
774
+2.71%
|
-
|
|
Mar 16
2025
|
Ross Moat CHIEF COMMERCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
292
-1.22%
|
$6,424
$22.61 P/Share
|
|
Mar 16
2025
|
Ross Moat CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
994
+4.0%
|
-
|
|
Mar 16
2025
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
448
-1.88%
|
$9,856
$22.61 P/Share
|
|
Mar 16
2025
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
872
+3.53%
|
-
|
|
Mar 16
2025
|
John F. Paolini CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
507
-0.94%
|
$11,154
$22.61 P/Share
|
|
Mar 16
2025
|
John F. Paolini CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,725
+3.11%
|
-
|
|
Mar 16
2025
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,004
-2.33%
|
$44,088
$22.61 P/Share
|
|
Mar 16
2025
|
Sanj K Patel CHAIRMAN & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,569
+7.09%
|
-
|
|
Mar 12
2025
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
36,372
-61.3%
|
$800,184
$22.25 P/Share
|
|
Mar 12
2025
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
36,372
+38.01%
|
$400,092
$11.97 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 24.4K shares |
|---|---|
| Exercise of conversion of derivative security | 741K shares |
| Payment of exercise price or tax liability | 43.5K shares |
|---|---|
| Open market or private sale | 667K shares |